3,7-Dinitrofluoranthene was evaluated by previous IARC Working Groups in 1988 and 1995 (IARC, 1989, 1996). New data have since become available, and these have been taken into consideration in the present evaluation.

1. Exposure Data

1.1 Chemical and physical data

1.1.1 Nomenclature

Synonym: 3,7-Dinitrofluoroanthene

1.1.2 Structural and molecular formulae and relative molecular mass

\[ \text{C}_{16}\text{H}_{8}\text{N}_{2}\text{O}_{4} \]
Relative molecular mass: 292.26 g/mol

1.1.3 Chemical and physical properties of the pure substance

Description: Yellow needles (Nakagawa et al., 1987)

Melting-point: 203–204 °C (Nakagawa et al., 1987)

Spectroscopy data: Nuclear magnetic resonance and ultraviolet spectral data have been reported (Ramdahl et al., 1988)

Octanol/water partition coefficient: \( \log K_{ow} = 4.44 \) (Lyman, 1985)

Vapour pressure (estimated): \( 9.1 \times 10^{-10} \) mm Hg at 25 °C (Lyman, 1985)

Boiling-point: 526.6 °C at 760 mm Hg (Guidechem, 2012)

Flash-point: 268.2 °C (Guidechem, 2012)

Density: 1.574 g/cm³ (Guidechem, 2012)

Solubility: Practically insoluble in water

1.2 Analysis

For a description of the analytical methods of \( N \)-polycyclic aromatic hydrocarbons in general, the reader is referred to Section 1.2.2(d) of the Monograph on Diesel Engine Exhausts.

Tokiwa et al. (1990) reported a method to separate and identify dinitrofluoranthenes in airborne particulates. The particulate matter was collected on a silica fibre filter and extracted with dichloromethane. The crude extracts were
applied to a column filled with silica gel and were eluted step by step with hexane, hexane:benzene (1:1, v/v), benzene, benzene:methanol (1:1, v/v) and methanol. The components were fractionated and identified by high-performance liquid chromatography and gas chromatography with mass spectrometry.

1.3 Production and use

3,7-Dinitrofluoranthene can be synthesized by the nitration of fluoranthene or 3-nitrofluoranthene in the presence of fuming nitric acid, followed by fractionation and purification by recrystallization (Nakagawa et al., 1987; Horikawa et al., 1991; Matsuoka et al., 1993).

No evidence was found that either 3,7- or 3,9-dinitrofluoranthene has been produced in commercial quantities or used for any purpose other than laboratory applications.

1.4 Occurrence and exposure

1.4.1 Natural occurrence

3,7-Dinitrofluoranthene is not known to occur as a natural product.

1.4.2 Environmental occurrence and exposure

Nitrofluoranthenes can be formed during the combustion of fossil fuels that contain fluoranthene, and from atmospheric reactions of fluoranthene with nitrogen oxides. Sources of nitrofluoranthenes include diesel emissions, combustion emissions from kerosene heaters, gas fuel, liquefied petroleum, airborne particles, coal-fly ash and food (Horikawa et al., 1987).

The use of 3,7-dinitrofluoranthene in laboratory applications may result in its release into the environment through various waste streams.

3,7-Dinitrofluoranthene was detected at a concentration of 0.028 mg/kg in particulates emitted from a diesel engine (Tokiwa et al., 1986).

In 1989, 3,7-dinitrofluoranthene was detected in airborne particulates at a level of 0.012 µg/g particulates, corresponding to 0.005 ng/m³, and in particulate emissions from a kerosene heater at 0.14 µg/g particulates in Sapporo, Hokkaido, Japan (Tokiwa et al., 1990).

Monitoring data indicated that exposure of the general population may occur through the inhalation of ambient air that contains 3,7-dinitrofluoranthene (HSDB, 2013).

2. Cancer in Humans

No data were available to the Working Group.

3. Cancer in Experimental Animals

3.1 Rat

See Table 3.1

3.1.1 Subcutaneous administration

Groups of 21 male Fischer 344/DuCrj rats (age, 6 weeks) received 3,7-dinitrofluoranthene (purity, 99.84%) by subcutaneous injection at a dose of 0 (control) or 0.05 mg dissolved in 0.2 mL of dimethyl sulfoxide twice per week for 10 weeks (total dose, 1 mg/rat). Animals were observed for 50 weeks; those with tumours at the site of injection were killed when moribund. The first subcutaneous tumour was observed in the treated group on day 155, and, within 48 weeks after the beginning of treatment, all treated rats had developed tumours at the site of injection; controls did not develop tumours. The incidence of tumours was highly statistically significant [21/21 (100%) versus 0/21; P < 0.001 Mann–Whitney U]. Twenty of 21 tumours were described as malignant fibrous histiocytoma and one as a rhabdomyosarcoma. Metastatic foci in the lungs were found in three rats. The mean tumour-induction time was 187 days (Tokiwa et al., 1987).
Table 3.1 Studies of the carcinogenicity of 3,7-dinitrofluoranthene in rats

<table>
<thead>
<tr>
<th>Strain (sex)</th>
<th>Route</th>
<th>Incidence of tumours</th>
<th>Significance</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>Dosing regimen</td>
<td>Animals/group at start</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F344/DuCrj  (M)</td>
<td>up to 50 wks</td>
<td>Tokiwa et al. (1987)</td>
<td>Subcutaneous injection 0, 0.05 mg/rat in DMSO (0.25 mg/mL), twice/wk for 10 wks (total, 1.0 mg or 3.42 μmol) then observed up to 50 wks 21 M/group (age, 6 wk)</td>
<td>Injection site (subcutaneous sarcoma): 0/21, 21/21 (100%)</td>
</tr>
<tr>
<td>F344 (M)</td>
<td>up to 100 wks</td>
<td>Horikawa et al. (1991)</td>
<td>Intrapulmonary implantation 0, 200 μg/rat in 0.05 mL beeswax:tricaprylin, injected directly into the left lower lung after thoracotomy then observed up until 100 wks 20 or 22 M/group (age, 11 wk)</td>
<td>Lung (all tumours): 0/19, 12/22 (54%) Lung (squamous-cell carcinoma): 0/19, 11/22 (50%) Lung (undifferentiated carcinoma): 0/19, 1/22 (5%)</td>
</tr>
</tbody>
</table>

DMSO, dimethyl sulfoxide; HPLC, high-performance liquid chromatography; M, male; wk, week

3.1.2 Intrapulmonary administration

Groups of 20 or 22 male Fischer 344/DuCrj rats (age, 11 weeks) received 3,7-dinitrofluoran-thene (purity, > 99.9%) as a single, direct implantation at a dose of 0 (control) or 200 μg in 0.05 mL of beeswax:tricaprylin vehicle into the left lung by thoracotomy under ketamine anaesthesia, and were then observed for up to 100 weeks. The incidence of tumours of the lung was 12 out of 22 (54%; 11 squamous cell carcinomas and one undifferentiated carcinoma) in the treated group and 0 out of 19 in the controls. The incidence of tumours was highly statistically significant [P < 0.0002, Mann–Whitney U]. The first tumour was observed at week 51 after the start of the experiment and 12 tumours developed by day 351 after injection (Horikawa et al., 1991).

4. Mechanistic and Other Relevant Data

3,7-Dinitrofluoranthene was considered by previous IARC Working Groups in 1988 and 1995 (IARC, 1989, 1996). Since that time, no new data have become available on the biological fate, metabolism, toxicity or carcinogenicity of this compound in experimental animals or in humans.

4.1 Absorption, distribution, metabolism, excretion

No data were available to the Working Group.

4.2 Genetic and related effects

4.2.1 Humans

No data were available to the Working Group.

4.2.2 Experimental systems

As reported in the previous IARC Monograph (IARC, 1989), 3,7-dinitrofluoranthene was highly active in the induction of reverse mutations in Salmonella typhimurium tester strains TA98, TA100, TA1538 and TA1537, but not in TA97, in the absence of a mammalian metabolic-activation system. Of these tester strains, TA98 was the most sensitive to 3,7-dinitrofluoranthene, indicating
In the parent strain, *S. typhimurium* TA1535/pSK1002, Nitroreductase and O-acetyltransferase activities were both required for the full stimulation of gene expression in the *umu* tester strains by 3,7-dinitrofluoranthene (*Oda et al.*, 1993). The NM3009 strain, which has both high nitroreductase and O-acetylation activity, was most sensitive to the *umu* gene expression induced by 3,7-dinitrofluoranthene and 1,6-dinitropyrene, followed by strains NM2009 and NM1011, which have O-acetyltransferase and nitroreductase activity, respectively. As expected, NM1000 and NM2000, which are deficient in nitroreductase and O-acetyltransferase activity, respectively, were less sensitive to 3,7-dinitrofluoranthene and 1,6-dinitropyrene (*Oda et al.*, 1993).

3,7-Dinitrofluoranthene also induced chromosomal aberrations in a Chinese hamster cell line in the absence of a rat-liver metabolic system *in vitro* (*Matsuoka et al.*, 1993), and micronucleus formation in mouse bone marrow *in vivo* (*Tokiwa et al.*, 1993).

### 4.3 Mechanistic considerations

3,7-Dinitrofluoranthene was carcinogenic in experimental animals (*IARC*, 1989; *Horikawa et al.*, 1991). Assays for genotoxicity and mutagenicity in bacteria indicated that 3,7-dinitrofluoranthene requires metabolic activation by xenobiotic-metabolizing enzymes to form active metabolites (*Nakagawa et al.*, 1987; *Oda et al.*, 1992, 1993; *Tokiwa et al.*, 1993). Although the details of the metabolism of 3,7-dinitrofluoranthene are unknown, this nitroarene may be considered to undergo bioactivation via a similar mechanism as that described for 3,9-dinitrofluoranthene.
5. **Summary of Data Reported**

5.1 **Exposure data**

3,7-Dinitrofluoranthene is present in diesel exhaust emissions and emissions from heaters fuelled with liquefied petroleum gas. No evidence was found that it has been produced in commercial quantities or for purposes other than laboratory applications. Due to its low vapour pressure, this substance is associated with the particulate phase of these combustion emissions. Exposure of the general population can occur through inhalation of airborne particulate matter in an urban environment, and may also occur from the domestic use of burners of liquefied petroleum gas. No data on occupational exposure were available to the Working Group.

5.2 **Human carcinogenicity data**

No data were available to the Working Group.

5.3 **Animal carcinogenicity data**

3,7-Dinitrofluoranthene was tested for carcinogenicity in rats by subcutaneous injection in one study and by intrapulmonary implantation in another study. Subcutaneous injection of 3,7-dinitrofluoranthene caused a significant increase in the incidence of malignant fibrous histiocytoma at the injection site. Implantation of 3,7-dinitrofluoranthene into the lung caused a significant increase in the incidence of carcinoma of the lung.

5.4 **Mechanistic and other relevant data**

No data were available to the Working Group on the absorption, distribution, metabolism or excretion of 3,7-dinitrofluoranthene in humans, experimental animals or in vitro, or on the genetic and related effects of 3,7-dinitrofluoranthene in humans. The compound was strongly mutagenic in bacteria, mainly as a frameshift mutagen. The mutagenicity was weaker in bacterial strains that are deficient in nitroreductase or in O-acetyltransferase, indicating that 3,7-dinitrofluoranthene is activated through nitroreduction and acetyltransfer. 3,7-Dinitrofluoranthene was genotoxic in the umu gene-expression assay, and induced chromosomal aberrations in Chinese hamster cells and micronucleus formation in the bone marrow of mice in vivo. It induced tumours in rats at the sites of subcutaneous injection and intrapulmonary implantation. The evidence suggests that this chemical produces mutagenic metabolites that could play a role in its carcinogenicity.

Overall, these data provide weak mechanistic evidence to support the carcinogenicity of 3,7-dinitrofluoranthene.

6. **Evaluation**

6.1 **Cancer in humans**

No data were available to the Working Group.

6.2 **Cancer in experimental animals**

There is sufficient evidence in experimental animals for the carcinogenicity of 3,7-dinitrofluoranthene.

6.3 **Overall evaluation**

3,7-Dinitrofluoranthene is possibly carcinogenic to humans (Group 2B).
References


Shimada T & Guengerich FP (1990). Inactivation of 1,3-, 1,6-, and 1,8-dinitropyrene by cytochrome P-450 enzymes in human and rat liver microsomes. Cancer Res, 50: 2036–2043. PMID:2180560


